Connection

Jean-Charles Soria to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Antibodies, Monoclonal, Humanized.
Jean-Charles Soria
Connection Strength
0.298
Antibodies, Monoclonal, Humanized
  1. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541.
    View in: PubMed
    Score: 0.145
  2. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209.
    View in: PubMed
    Score: 0.039
  3. Reply to F. Tomao et al. J Clin Oncol. 2017 11 01; 35(31):3633-3634.
    View in: PubMed
    Score: 0.037
  4. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 2017 03 13; 15(1):55.
    View in: PubMed
    Score: 0.036
  5. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 2021 03 11; 12(3):258.
    View in: PubMed
    Score: 0.012
  6. Bull Cancer. 2018 Dec; 105 Suppl 1:S59-S67.
    View in: PubMed
    Score: 0.010
  7. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2019 02 01; 25(3):946-956.
    View in: PubMed
    Score: 0.010
  8. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.